Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4351 | 1725 | 30.7 | 58% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1439 | 7339 | BNCT//BORON NEUTRON CAPTURE THERAPY//TIRAPAZAMINE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | TIRAPAZAMINE | Author keyword | 97 | 68% | 5% | 86 |
2 | HYPOXIC CELL RADIOSENSITIZER | Author keyword | 55 | 92% | 1% | 22 |
3 | KU 2285 | Author keyword | 42 | 94% | 1% | 15 |
4 | SR 2508 | Author keyword | 42 | 94% | 1% | 15 |
5 | AQ4N | Author keyword | 38 | 89% | 1% | 17 |
6 | BIOREDUCTIVE DRUGS | Author keyword | 37 | 57% | 3% | 44 |
7 | PR 104 | Author keyword | 34 | 93% | 1% | 13 |
8 | SR 4233 | Author keyword | 29 | 73% | 1% | 22 |
9 | ETANIDAZOLE | Author keyword | 28 | 57% | 2% | 34 |
10 | DORANIDAZOLE | Author keyword | 27 | 92% | 1% | 11 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TIRAPAZAMINE | 97 | 68% | 5% | 86 | Search TIRAPAZAMINE | Search TIRAPAZAMINE |
2 | HYPOXIC CELL RADIOSENSITIZER | 55 | 92% | 1% | 22 | Search HYPOXIC+CELL+RADIOSENSITIZER | Search HYPOXIC+CELL+RADIOSENSITIZER |
3 | KU 2285 | 42 | 94% | 1% | 15 | Search KU+2285 | Search KU+2285 |
4 | SR 2508 | 42 | 94% | 1% | 15 | Search SR+2508 | Search SR+2508 |
5 | AQ4N | 38 | 89% | 1% | 17 | Search AQ4N | Search AQ4N |
6 | BIOREDUCTIVE DRUGS | 37 | 57% | 3% | 44 | Search BIOREDUCTIVE+DRUGS | Search BIOREDUCTIVE+DRUGS |
7 | PR 104 | 34 | 93% | 1% | 13 | Search PR+104 | Search PR+104 |
8 | SR 4233 | 29 | 73% | 1% | 22 | Search SR+4233 | Search SR+4233 |
9 | ETANIDAZOLE | 28 | 57% | 2% | 34 | Search ETANIDAZOLE | Search ETANIDAZOLE |
10 | DORANIDAZOLE | 27 | 92% | 1% | 11 | Search DORANIDAZOLE | Search DORANIDAZOLE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SR 4233 | 143 | 73% | 6% | 110 |
2 | 3 AMINO 1 2 4 BENZOTRIAZINE 1 4 DIOXIDE TIRAPAZAMINE | 65 | 95% | 1% | 21 |
3 | 1 2 4 BENZOTRIAZINE 1 4 DIOXIDES | 45 | 90% | 1% | 19 |
4 | MISONIDAZOLE | 39 | 30% | 6% | 109 |
5 | BIOREDUCTIVE AGENT | 38 | 78% | 1% | 25 |
6 | RSU 1069 | 34 | 59% | 2% | 38 |
7 | TIRAPAZAMINE | 33 | 45% | 3% | 55 |
8 | 3 AMINO 1 2 4 BENZOTRIAZINE 1 4 DIOXIDE | 30 | 79% | 1% | 19 |
9 | HYPOXIC CELL RADIOSENSITIZERS | 29 | 58% | 2% | 34 |
10 | REDUCTIVE BIOACTIVATION | 27 | 76% | 1% | 19 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CANCER CLINICAL TRIALS | 3 | 16% | 1% | 20 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia | 2014 | 11 | 69 | 59% |
Exploiting tumour hypoxia in cancer treatment | 2004 | 764 | 118 | 38% |
Targeting hypoxia in cancer therapy | 2011 | 391 | 166 | 25% |
Design of Anticancer Prodrugs for Reductive Activation | 2009 | 129 | 198 | 36% |
The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award lecture | 1999 | 410 | 74 | 30% |
SR-4233 (TIRAPAZAMINE) - A NEW ANTICANCER DRUG EXPLOITING HYPOXIA IN SOLID TUMORS | 1993 | 236 | 52 | 63% |
Bioreductive drugs: from concept to clinic | 2007 | 91 | 155 | 46% |
Hypoxia-activated prodrugs in cancer therapy: progress to the clinic | 2010 | 28 | 56 | 66% |
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies | 2000 | 221 | 24 | 42% |
Hypoxia-specific cytotoxins in cancer therapy | 1996 | 69 | 88 | 59% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AUCKLAND CANC SOC | 12 | 14% | 4.6% | 80 |
2 | EXPT ONCOL GRP | 2 | 22% | 0.5% | 8 |
3 | AUCKLAND CANC SOCIETY | 1 | 38% | 0.2% | 3 |
4 | DCTDFAIRVIEW | 1 | 100% | 0.1% | 2 |
5 | ONCOL RADIAT ONCOLRADIOBIOL | 1 | 100% | 0.1% | 2 |
6 | PHYS 500 SHERBOURNE ST | 1 | 27% | 0.2% | 3 |
7 | CANC SOC | 1 | 17% | 0.3% | 5 |
8 | RADIAT SCI GRP | 1 | 17% | 0.2% | 4 |
9 | BREAST BIOL CANC UNIT | 1 | 50% | 0.1% | 1 |
10 | CALIF CANC CONSORTIUM | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000214596 | QUIESCENT CELL//BORON TRACEDRUG//MILD TEMPERATURE HYPERTHERMIA |
2 | 0.0000207657 | KIMMELL CANC//MERCURY ORANGE//ANTI SINGLE STRANDED DNA ANTIBODY |
3 | 0.0000203853 | CARBOGEN//TUMOR HYPOXIA//TUMOR OXYGENATION |
4 | 0.0000124585 | MED MEANS CHEM//EMIZCO//P NITROACETOPHENONE |
5 | 0.0000100945 | NITRO RADICAL ANION//NIFURTIMOX//BIOELE OCHEM |
6 | 0.0000085067 | CB1954//ADEPT//ANTIBODY DIRECTED ENZYME PRODRUG THERAPY |
7 | 0.0000065460 | DT DIAPHORASE//EO9//NQO1 |
8 | 0.0000060492 | FLUOSOL//PERFLUOROCHEMICAL EMULSION//BIOMATERIALS ARTIFICIAL CELLS AND ARTIFICIAL ORGANS |
9 | 0.0000059278 | LOW DOSE HYPER RADIOSENSITIVITY//HYPER RADIOSENSITIVITY//ULTRAFRACTIONATION |
10 | 0.0000053678 | FRACTIONATED X IRRADIATION//RAT YOLK SAC TUMOR//DRUG EFFECT ON BRAIN |